Prostamax

As research shows

Prostamax (KEDP) belongs to the class of short bioregulatory peptides studied by Khavinson and colleagues. These tetrapeptides are proposed to modulate gene expression through epigenetic mechanisms, interacting with chromatin structure and histone proteins. In aged human lymphocytes, KEDP has been observed to cause pericentromeric chromatin decondensation, potentially reactivating suppressed genes. Preclinical rat models of prostatitis showed that IM administration of KEDP reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue

Key benefits

• In rat prostatitis models, IM KEDP administration reduced inflammation and supported tissue normalization over treatment periods of 15–60 days.
• Studies in benign prostatic hyperplasia (BPH) models showed favorable effects on prostate weight and histological parameters.
• Short bioregulatory peptides of this class generally show favorable tolerability profiles in preclinical work